On December, 13 The EPS for Spero Therapeutics, Inc. (SPRO) Expected At $-0.64

November 8, 2018 - By Glen Chin

Spero Therapeutics, Inc. (NASDAQ:SPRO) Corporate Logo

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s earnings report is anticipated on December, 13., as reported by Faxor. Last year’s earnings per share was $-36.02, while now analysts expect change of 98.22 % up from current $-0.64 earnings per share. After $-0.69 earnings per share was reported last quarter, analysts now see EPS growth of -7.25 % for Spero Therapeutics, Inc.. SPRO reached $9.18 during the last trading session after $0.55 change.Spero Therapeutics, Inc. has volume of 46,333 shares. Since November 9, 2017 SPRO has 0.00% and is . SPRO underperformed the S&P 500 by 15.62%.

Spero Therapeutics, Inc. (NASDAQ:SPRO) Ratings Coverage

A total of 3 analysts rate Spero Therapeutics (NASDAQ:SPRO) as follows: 2 “Buy”, 0 “Hold” and 1 “Sell”. Тherefore 67% are bullish. (NASDAQ:SPRO) has 4 ratings reports on Nov 9, 2018 according to StockzIntelligence. On Thursday, May 10 the firm has “Buy” rating given by Cantor Fitzgerald. On Tuesday, October 16 the company was downgraded by Bank of America. On Friday, May 11 the rating was initiated by H.C. Wainwright with “Buy”.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant bacterial infections in the United States.The company has $166.79 million market cap. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.Last it reported negative earnings.

For more Spero Therapeutics, Inc. (NASDAQ:SPRO) news announced briefly go to: Nasdaq.com, Nasdaq.com, Seekingalpha.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Mid-Day Market Update: Dow Rises Over 350 Points; Hanwha Q CELLS Shares Spike Higher” announced on October 16, 2018, “Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview” on November 08, 2018, “Spero Therapeutics receives QIDP designation for the development of SPR206” with a publish date: October 11, 2018, “Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial” and the last “New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero …” with publication date: October 17, 2018.

Spero Therapeutics, Inc. (NASDAQ:SPRO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.